Report #2841743

Received May 20, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: WA
Recovered: Unknown
Vaccinated: May 16, 2025
Onset: May 16, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	UNK	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

interval too long between dose 1st and 2nd dose; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a adult female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose on 09-OCT-2021). On 16-MAY-2025, the patient received the 2nd dose of Shingrix. On 16-MAY-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: interval too long between dose 1st and 2nd dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK receipt date: 16-MAY-2025 The patient self-reported this case for herself. The patient received 2nd dose of Shingrix, later than the recommended interval, which led to lengthening of vaccination schedule.